Beckman Coulter Has Pact

FULLERTON —  Beckman Coulter Inc. and Immunomedics Inc. said Tuesday they have tentatively agreed to form a cancer pharmaceuticals venture in New Jersey. Terms weren’t disclosed.

Beckman Coulter said it will contribute proprietary technology to the venture, to be named IBC Pharmaceuticals, and it will work with Immunomedics to raise outside private capital.

The venture company, which will be in Morris Plains, will focus on a therapy that delivers radioisotopes to cancer cells.

Fullerton-based Beckman Coulter makes systems for blood and other cell analysis. Immunomedics, which is based in Morris Plains, is a biopharmaceutical company.